Posted in | News | Laser

Insider Information: Modulight’s ML6710i Laser Device Approved by FDA for AMD Treatment

Modulight Corp. has received an approval from the US Food and Drug Administration FDA for its ML6710i laser device for the treatment of wet age-related macular degeneration (AMD) in the United States, which was already expected in 2021 and discussed in the listing prospectus.

The company started cooperating with Bausch + Lomb on the preparation of a marketing authorization application for the US Food and Drug Administration FDA already in 2018. Now the company has received information about the approval. The company will start launching the product in the US without delay.

The ML6710i is a new type of medical laser device designed to treat various eye diseases. It is very easy to use and works with the iPad. All operating parameters and laser usage events are securely stored in the Modulight Cloud treatment log.

In 2018, Bausch + Lomb, the world's leading company focusing on the treatment of eye diseases, and Modulight signed an exclusive cooperation agreement for the development of laser devices that work with the company's VISUDYNE® drug. VISUDYNE® is an injectable photosensitizer for the treatment of patients with choroidal neovascularization due to age-related macular degeneration (AMD) or other causes. The VISUDYNE® drug is activated with Modulight ML6710i Laser.

"Modulight works closely with healthcare companies to tailor its wide range of laser technology solutions to meet their needs in particular. Our collaboration with Bausch + Lomb has continued for several years, and together we have succeeded in developing a top-class laser. Now that we have received approval in the US market, we will be able to bring this product on sale”, commented Modulight’s CEO Seppo Orsila.

Modulight has submitted the product's marketing authorization application also in the European Union, where the authorization is expected this year.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Modulight, Inc.. (2023, January 25). Insider Information: Modulight’s ML6710i Laser Device Approved by FDA for AMD Treatment. AZoOptics. Retrieved on June 24, 2024 from https://www.azooptics.com/News.aspx?newsID=28166.

  • MLA

    Modulight, Inc.. "Insider Information: Modulight’s ML6710i Laser Device Approved by FDA for AMD Treatment". AZoOptics. 24 June 2024. <https://www.azooptics.com/News.aspx?newsID=28166>.

  • Chicago

    Modulight, Inc.. "Insider Information: Modulight’s ML6710i Laser Device Approved by FDA for AMD Treatment". AZoOptics. https://www.azooptics.com/News.aspx?newsID=28166. (accessed June 24, 2024).

  • Harvard

    Modulight, Inc.. 2023. Insider Information: Modulight’s ML6710i Laser Device Approved by FDA for AMD Treatment. AZoOptics, viewed 24 June 2024, https://www.azooptics.com/News.aspx?newsID=28166.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.